Profile picture of James Fletcher

Dr James Fletcher

Profile picture of James Fletcher

BSc, MBBS, FRACP

Medical Oncologist
Call
Enquire
Referrals

Dr James Fletcher brings a holistic, evidence-based approach to his practice and is dedicated to delivering comprehensive and patient-centred care. He is a strong advocate for clinical trials and local research, ensuring that his patients have access to the latest treatment options.

Biography

Dr James Fletcher is a consultant medical oncologist at Icon Cancer Centre Southport. He completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Queensland and undertook specialist medical oncology training across Queensland’s tertiary hospital network. In 2020 Dr Fletcher became a medical oncology fellow at the Royal Australasian College of Physicians (FRACP) and in 2021 completed his dual training as a general physician. He subsequently commenced a medical oncology research fellowship at the Princess Alexandra Hospital and became a PhD candidate at the University of Queensland.

With a passion for research, clinical trials and medical education, Dr Fletcher holds academic appointments at Griffith University’s School of Medicine and the University of Queensland’s School of Clinical Medicine at the Princess Alexandra Hospital. He has published in peer-reviewed journals, been awarded research grants for collaborative research protocols and clinical trials, and been an invited speaker at local and national conferences to present on lung cancer and geriatric oncology. His clinical experience covers a broad range of solid tumour malignancies with a special interest in lung cancer, gastrointestinal cancer, and geriatric oncology.

Publications

  • Fletcher, J.A. Patient derived goals. Asia-Pacific Journal of Clinical Oncology. 2022;18(Suppl 3.):53-113.

  • Fletcher, J.A., Fox, S., Reid, N., Hubbard, R.E., Ladwa, R. The impact of frailty on health outcomes in older adults with lung cancer: a systematic review. Cancer Treatment and Research Communications. 2022;33:100652.

  • Fletcher, J., Bird, R., McLean, J.W., O’Byrne, K., Xu, W. Acquired hemophilia A secondary to an immune checkpoint inhibitor: case report. Journal of Thoracic Oncology Clinical and Research Reports. 2022;3(11):100409.

  • Fletcher, J., Reid, N., Hubbard, R.E., Berry, R., Weston, M., Walpole, E., Kimberley, R., Ladwa, R. EP04.01-013 Frailty index predicts treatment outcomes in older adults with lung cancer. Journal of Thoracic Oncology. 2022;17(9):S251.

  • O’Leary, C., Fletcher, J., Yuile, A., Xu, W., Ladwa, R., McGrath, M., Pavlakis, N., Hughes, B., McCaffery, E., O’Byrne, K. Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Asia-Pacific Journal of Clinical Oncology. 2020;16(S2):12.

Special Interests

Dr James Fletcher accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Gastrointestinal cancer
  • Geriatric oncology
  • Lung cancer
  • Prostate cancer

Languages spoken

  • English

Icon Locations

Visiting Locations

  • Gold Coast Private Hospital
  • Pindara Private Hospital
  • John Flynn Private Hospital

Affiliations & Memberships

  • American Society of Clinical Oncology (ASCO)
  • Clinical Oncology Society of Australia (COSA)
  • eviQ Medical Oncology Reference Committee
  • International Society of Geriatric Oncology (SIOG)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)
  • Thoracic Oncology Group of Australasia (TOGA)

Publications

  • Fletcher, J.A. Patient derived goals. Asia-Pacific Journal of Clinical Oncology. 2022;18(Suppl 3.):53-113.

  • Fletcher, J.A., Fox, S., Reid, N., Hubbard, R.E., Ladwa, R. The impact of frailty on health outcomes in older adults with lung cancer: a systematic review. Cancer Treatment and Research Communications. 2022;33:100652.

  • Fletcher, J., Bird, R., McLean, J.W., O’Byrne, K., Xu, W. Acquired hemophilia A secondary to an immune checkpoint inhibitor: case report. Journal of Thoracic Oncology Clinical and Research Reports. 2022;3(11):100409.

  • Fletcher, J., Reid, N., Hubbard, R.E., Berry, R., Weston, M., Walpole, E., Kimberley, R., Ladwa, R. EP04.01-013 Frailty index predicts treatment outcomes in older adults with lung cancer. Journal of Thoracic Oncology. 2022;17(9):S251.

  • O’Leary, C., Fletcher, J., Yuile, A., Xu, W., Ladwa, R., McGrath, M., Pavlakis, N., Hughes, B., McCaffery, E., O’Byrne, K. Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Asia-Pacific Journal of Clinical Oncology. 2020;16(S2):12.

Search

Contact us
Become a patient